Heterozygous and homozygous deletions of chromosome 13q14.3 are found in 50% of patients with B cell CLL, suggesting the presence of one or more tumour suppressor genes within the deleted region. To identify candidate genes from the region, we constructed a map of 13q14.3 using a combination of genomic and cDNA library screening. The incidence of deletions in CLL patients was 51.5% encompassing a 265 kb region of minimal deletion (RMD) telomeric to markers D13S319. Two CpG islands were identified within the RMD, the telomeric of which is fully methylated whilst the more centromeric is unmethylated. A novel transcript was identified within the RMD that represents an alternative splice version of Leu1. The nine exons of this transcript span a genomic of 436 kb with exon 1 of Leu1 being the common first exon. The remaining exons were shown to be more frequently deleted than Leu1 itself. All splice forms of this transcript were detectable by RT-PCR but Leu1 detected the most abundant message on Northern blotting. Sequence analysis failed to reveal inactivating mutations in patients with heterozygous deletion of 13q14.3, although a polymorphic T to A variant was identified within exon 1 of Leu1 in leukemic and normal controls. As no mutations have been detected for Leu1 or any other transcript so far described, we cannot exclude the existence of control elements within the RMD that may regulate expression of genes lying in this region.
Introduction

B cell chronic lymphocytic leukemia (CLL) is characterized by a clonal expansion of CD5
+ B cells and is the commonest leukemia in the western world. The etiology of B cell CLL remains unknown. A variety of cytogenetic abnormalities have been described in B cell CLL. Deletion of the long arm of chromosome 13 (13q14.3) is however the commonest, with reported frequencies of 41-51%, [1] [2] [3] but 13q being also commonly deleted in a variety of other lymphoid and myeloid malignancies. [4] [5] [6] [7] [8] [9] In the majority of cases, deletion of 13q14.3 is the sole cytogenetic abnormality 10, 11 and approximately 10% of CLL patients show homozygous deletion at this locus. Consequently, the existence of a tumor suppressor gene within the deleted region at 13q14.3, involved in the pathogenesis of B cell CLL, has long been postulated.
The minimal region of deletion at 13q14.3 has been found to vary in different studies of CLL patients. Some groups have found the region to be located around the marker D13S319, 1, 3, 12 whilst others have described a more telomeric region of deletion close to the marker D13S25. 13, 14 There is a central area of overlap between the different RMDs described in these studies of approximately 300 kb, which concurs with our previously published data. 2 Three candidate tumour suppressor genes from 13q14.3 have been identified in this area to date. 15, 16 The first gene described, Leu1, consists of two exons and has a predicted open reading frame encoding for a 72 amino acid peptide. The gene is located centromeric of D13S319, within the RMD described by Corcoran et al 1 and Kalachikov et al, 12 but outside the RMD described by Bouyge-Moreau et al 13 and Bullrich et al. 14 Extensive sequence analysis has failed to detect mutations in the genomic sequence of Leu1 in any CLL patients carrying heterozygous deletion of 13q14.3. 15, 16 The second gene, Leu2, was also isolated from the same RMD. 1 This gene consists of two exons and has a predicted open reading frame encoding for an 84 amino acid protein. Similar to analysis of Leu1, no mutations were demonstrated in 170 CLL patients, 15 and this gene has been excluded as a candidate tumor suppressor gene by some investigators. 17 A third gene, Leu5, (alternative name CAR) has also been described. 15, 18 The deduced protein sequence of this gene shares significant homology with the RET finger protein and the well-known tumour suppressor gene BRCA1. The gene encodes for a postulated 407 amino acid peptide. However, this gene lies outside the RMD described by all groups and no mutations have been demonstrated in patients with CLL, to date.
In this study we aimed to map the region of deletion at 13q14.3, to define the region of minimal deletion in our cohort of patients with CLL and to identify and characterize candidate tumor suppressor genes from the deleted region.
We initially constructed a contig across the area using a combination of plasmid, bacterial and yeast genomic clones (PAC, BAC and YAC). Patients' DNA was analyzed by Southern blotting for deletion of probes from 13q14.3.
In order to identify candidate tumor suppressor gene transcripts from the 13q14.3 region we used a combination of Get exon trapping, 19 cDNA library screening and rapid amplification of cDNA ends (RACE) PCR. This analysis lead to the redefinition of the region of minimal deletion and the identification of a novel and longer alternative spliced form of Leu1. This longer transcript is found almost exclusively in nuclear RNA extracts whilst Leu1 is found in cytoplasmic RNA fractions. Either directly or via inactivation of Leu1 itself, this transcript may contribute to the malignant phenotype of CLL by deletion, haplo-insufficiency or loss of other genomic control elements from the region, yet with unknown mechanistic effects.
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Materials and methods
Patient material
Material from 64 patients was investigated. The diagnosis of CLL was based on clinical history, lymphocyte morphology and immunophenotype criteria. 20 B lymphocytes were harvested from 20 ml of peripheral blood as previously described. 21 DNA was made using a Puregene DNA extraction kit (Gentra, Flowgen, Litchfield, UK) following the manufacturer's instructions.
DNA probes and Southern blot analysis
Southern blot analysis was carried out as previously described. 21 Single copy genomic probes used for analysis of the minimal region of deletion were as follows: D13S25 (21) and D13S319 (a gift from S Einhorn, Karolinska Institute, Stockholm, Sweden), probe 1c (sequence identified through accession No. AA431979), 468HTF (PCR amplification of a genomic region containing a CpG island 265 kb telomeric to D13S319) and 49G7T7. 12 Primers for amplification of novel probes isolated from 13q14.3 by exon trapping, cDNA library screening and RACE PCR are shown in Table 1 while their Primers for (1) amplification of DNA genomic probes, (2) RACE PCR and (3) mutational and expression analysis. The name of each probe and the genomic fragment that it recognizes are also listed.
location is shown in Figure 1 (layers 2 and 3; solid black boxes). All genomic Southern blot filters were simultaneously hybridized to either a probe for the TCRD constant region (14q11) 23 or a genomic fragment for the APC gene (5q31) 21 to control for the loaded amount of DNA. Clonality of all samples was assessed by hybridization to the immunoglobulin J H probe as described. 21 
DNA sequencing
DNA sequencing of genomic clones was performed by either the dideoxy chain termination system 24 or using an ABI Prism 377 automated sequencer (Perkin Elmer, Warrington, UK) according to the manufacturer's instructions. Searches for homologous sequences were performed using the BLAST analysis program (http://www.ncbi.nlm.nih.gov). All BAC clones were fully sequenced at the Sanger Centre, Cambridge, UK using a shotgun-method, previously described.
Figure 1
Physical map of the deleted region at 13q14.3. The seven layers schematically represent mapping the region of minimal deletion at 13q14.3 in B cell CLL as follows: Layer 1: the RMD derived from this study spans a genomic distance of 265 kb between markers D13S319 and 468HTF. Layer 2: 25 unique microsatellites, ESTs and STSs from the region were included in the map. The individual genomic probes used for investigation of the RMD are shown by black boxes. Layer 3: position of exons identified from novel transcripts, isolated through cDNA library screening and RT-PCR, as described further in the text. Again, all markers used as probes are depicted by a black box. Layers 4-7: position of PAC, BAC, genomic sequences and YAC clones used in mapping the region. All clone lengths are drawn to scale. We refer to the text for a more extensive description of each individual layer.
Screening of genomic libraries
In order to construct a contig of genomic clones across the deleted region of 13q14.3, a combination of PAC, BAC and YAC libraries were screened. The ICI YAC genomic library (Human Genome Mapping Project, Medical Research Council, Cambridge, UK -HGMP) was initially screened by PCR for the markers D13S25 and D13S319. In addition, a series of CEPH clones known to be located within the deleted region were screened. 26 All YAC clones were checked for chimerism using metaphase FISH as previously described. 27 The size of each YAC was ascertained by PFGE analysis. 28 All PAC and BAC clones were obtained from HGMP. Further markers from the region were identified from the Whitehead Institute Database (http://www.genome.wi.mit.edu) and the Genome Database (http://www.gdb.org) and these were used to accurately assemble the genomic contigs.
get exon trapping
Exon trapping was performed using YAC 933e9 as a template genomic clone, with DNA prepared as described preLeukemia viously. 29, 30 The DNA was partially digested into approximately 19 kb fragments with the restriction enzyme SalI, and was cloned into the exon trapping phage vector Get. 19 Following plating of the phage library, all clones containing genomic DNA were selected by hybridization to total human DNA labelled with ␣-32 P-dCTP.
cDNA library screening
Two cDNA libraries were screened. The first was derived from peripheral leukocyte RNA, constructed in the phage vector rpD2 (Clontech, Palo Alto, CA, USA). Approximately 10 6 plaques were screened by hybridization to a 199 bp single copy probe (exon 7 in Figure 1 , layer 3) isolated by exon trapping of YAC 933e9. The positive phage clones were converted to plasmids by infecting a Cre-recombinase expressing Escherichia coli strain, BNN 132. The plasmid DNA was then purified and the plasmid inserts were subcloned into the Bluescript KS + plasmid vector for sequencing. The second cDNA library used was also derived from peripheral leukocyte RNA, was constructed in the plasmid vector pCMV Sport (GibcoBRL) and propagated in ElectroMAX DH12S cells. Approximately 10 6 colonies were screened with a cDNA probe designed from cDNA clone 1 as described below.
RACE PCR
Both 3Ј and 5Ј RACE PCR was performed to extend cDNA transcripts prepared from thymic RNA (Clontech, Palo Alto, CA, USA) using the Marathon cDNA amplification kit (Clontech). Gene specific primers were designed from clones identified by cDNA library screening (Table 1) .
Expression analysis
Northern blot filters containing 2 g of poly (A)+ from a range of human tissues were hybridized according to the manufacturer's protocol (Clontech).
Mutational analysis
Mutations in both DNA and RNA of candidate tumor suppressor gene transcripts were assessed from patients with heterozygous deletion of 13q14.3. Exon specific sequences and intron-exon boundaries were amplified by a combination of genomic PCR, using primers designed from intronic sequence, and RT-PCR using exon-specific primers (Table 1) . PCR reactions were examined by agarose gel electrophoresis and cloned into the plasmid Bluescript KS + prior to sequencing. Sequence analysis was carried out using DNASTAR software.
CpG island identification and characterization
In order to identify CpG islands from the region at 13q14.3, the complete DNA sequence was analyzed for the presence of clusters of methylation-sensitive restriction enzyme sites. The methylation status of the CpG islands was then analyzed as follows: DNA obtained from normal and leukemic lymphocytes was assessed by restriction enzyme digest using SacII, BssHII, NotI and NarI in a double digest with HindIII. Probes derived from individual CpG islands were hybridized to genomic clones containing the rare cutter sites to confirm the methylation status of each region. The failure of the additional restriction enzymes to further digest a HindIII fragment confirmed the fully methylated status of the CpG island whilst reduction in size of the expected HindIII fragment suggested an unmethylated site. The 468p13HTF probe was tested on five controls, and three CLL patients, while the D13S319 probe was tested on four controls, 10 leukemic acute lymphoblastic leukemia (ALL) and three CLL patients.
Extraction of nuclear and cytoplasmic RNA
RNA was extracted from both nuclear and cytoplasmic fractions of CLL cells (four patients) and two normal controls, using an adaptation of Chomczynski's method. 31 In brief, 0.5% NP40 buffer (10 mM TrisCl pH 7.4, 10 mM NaCl and 3 mM MgCl 2 ) supplemented with RNasin and 0.1 M DTT was used to wash the cell pellets before extraction with 10% SDS and neutral phenol (Sigma, Poole, UK).
Results
Physical mapping and sequencing of the deleted region
A physical map of the deleted region at 13q14.3 between markers D13S319 and D13S25 was constructed with layers of genomic clones forming a continuous contig across the minimal region of deletion. A total of 35 markers were used as shown in layers 2 and 3 of Figure 1 . Since completion of this work, the full sequence of this region has become available (GenBank accession No. AF272953). The region of interest to this study spans a distance of 540 kilobases between the markers 175B12-361 and D13S25.
Four YAC clones were identified from the CEPH (Y933e9) and the ICI libraries (Y32EH6, Y11AF3 and Y39FC12) (layer 7 of Figure 1 ). Five PAC clones, derived from a previous report, 12 were also available ( Figure 1, layer 4) . Single copy probes from PAC 55o6 identified BACs 460F10 and 468P13 (Figure 1 Defining the minimally deleted region in our patients at 13q14.3
DNA from a total of 64 patients with CLL was screened by Southern blotting for deletion of 12 unique genomic probes from 13q14.3 (black boxes in layers 2 and 3, Figure 1) . Results from informative patients (defining the borders of the minimal region of deletion) are shown in Figure 2 . Thirty-three (51.6%) patients carried deletion of 13q14.3 with nine (14%) showing homozygous deletion of the entire region. A further 24 (37.5%) were found to have heterozygous deletion. Patients 7, 11 and 12 were critical in defining the boundaries of the RMD as being between D13S319 and 468HTF ( Figure 2 ). This is a genomic distance of 265 kb (Figure 1, layer 1) , with the centromeric boundary between D13S319 and 49G7T7 (a distance of 135 kb) and a telomeric boundary between exon 3 and 468HTF (a distance of 6 kb). When this region is compared to RMD described by other investigators 3,12-14 the minimally deleted region can be reduced to 230 kb in total. In addition, two of the patients (patients 11 and 22, Figure 2 ) had non-contiguous homozygous deletion of 13q14.3. Others have noted similar non-contiguous deletions of 13q14.3 both by FISH, 3 and by Southern blot analysis.
12
CpG island characterization
The full DNA sequence of the region was analyzed for the presence of gene-associated CpG island sequences. Two were identified, one 7.9 kb centromeric of D13S319 and the other 266 kb telomeric of D13S319 ( Figure 1, layer 3 ). These were verified by Southern blot analysis of BAC and PAC clones containing the clusters of rare cutters. The methylation pattern of the CpG island adjacent to D13S319 was assessed by Southern blotting and was shown to be totally unmethylated whilst the more telomeric was found to be fully methylated ( Figure 3 ). This pattern was consistent in both normal and leukemic (CLL and ALL) cells analyzed.
Identifying candidate tumor suppressor gene cDNA sequences from 13q14.3
Get exon trapping of YAC 933e9 identified a putative 199-bp exon (exon 7, Figure 1 ) which mapped to the deleted region at 13q14.3. A probe containing this sequence was hybridized to a peripheral leukocyte cDNA library, identifying a 1.7 kb polyadenylated clone (cDNA clone 1, Figure 4 ) with exon 7 located 500 bp from the 5Ј end. cDNA clone 1 identified six discrete bands on an EcoRI Southern blot DNA digest (data not shown). However, no signal was detectable in patients with homozygous deletion of 13q14.3 between D13S319 and D13S25. A 685-bp single copy probe, obtained from the 5Ј end of clone 1, was hybridized to a second peripheral leukocyte cDNA library. A 922-bp polyadenylated clone, cDNA clone 2 ( Figure 4 ) was isolated, which corresponded to the published sequence of Leu1, 15 except for the absence of a thymine at position 536 of Leu1 sequence ( Figure 5 ). This change was also confirmed in clones amplified from genomic DNA (data not shown) and resulted in an open reading frame (ORF) six amino acids (AA) longer (78 AA) than the previously published sequence of Leu1 (72 AA). 15 Clone 2 (Leu1) identified a 1.1 kb message on a lymphoid Northern blot (Clontech; not shown) as previously reported. 15 RT-PCR using primers C12T7(5)-F and C12T3(6)-R, 15 amplified two alternatively spliced forms of Leu1; the longer resulting from the insertion of exon 1b (Figures 1, 4 and 5) . Both spliced forms are present in control and leukemic cells. CpG islands methylation pattern. Southern blot analysis using total genomic DNA digested with HindIII alone or in combination with rare cutters as indicated. Left panel shows results of Southern blot analysis following hybridization to a probe derived from the D13S319 region. The right panel results were obtained using a probe derived from 468p13 region. (See Figure 1 for position of individual probes, Table 1 for primers specific used to generate probe 468HTF and text for further details.) * Highlights fragments digested by methylation-sensitive enzymes.
Further characterization of cDNA clone 1
The overall structure of clone 1 is illustrated in Figure 4 (version 1). The first 2 exons of Leu1 (exons 1 and 1b) are spliced to exons 3, 4, 7-9 in cDNA clone 1. To further charac-
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Figure 4
Leu1 and alternative spliced forms from this study. This figure summarizes the different alternative splice versions of Leu1 that were isolated in this study. The initial Leu1 wild-type transcript (clone 2) is shown, with the other splice versions represented subsequently. cDNA clone 1 (version 1) was isolated by screening of a lymphoid cDNA library with a probe for exon 7. Version 2 was isolated by RT-PCR using primers derived from exons 1 and 2. Versions 3-6 were isolated by Marathon RACE PCR using anchor primers from exon 3, and their existence was confirmed by RT-PCR in both normal and malignant lymphocytes.
terize this transcript, 5Ј and 3Ј nested RACE PCR was employed using anchor primers from exon 3 and 7 (Table 1 ). Figure 4 illustrates the different spliced transcripts identified both in normal and malignant lymphoid cells.
In total, nine exons were identified by cDNA library screening and RACE PCR. Exons 3-5 were subsequently shown to correspond to EST AI337241 and exons 5 and 6 corresponded to EST AA431979. As clone 1 shares the first exon of Leu1, it appears to be an alternative transcript of that gene. Intron- exon boundaries of all exons were identified (Table 2) allowing the genomic organization of all clones (Figure 1 , layer 3 and Figure 4 ). Each exon is flanked by appropriate splice donor-acceptor sites (Table 2) . Significantly, the full clone 1 spans a large genomic distance of 436 kb with exons mapping both to the minimal region of deletion in our patients and that described by others 3, 12, [14] [15] [16] (Figure 1 ). Probes from each individual exon of cDNA clone 1 were hybridized to a Northern blot of lymphoid tissue RNA. No signal could be identified with the exception of the 1.1 kb message detected by Leu1 exon 1, suggesting that this exon is the most abundantly transcribed part of the message. Expression of the remaining exons was detectable by RT-PCR in normal and malignant lymphocytes. Table 2 Intron-Exon boundaries of Leu1 alternative splice transcript from 13q14. 
Mutational analysis in leukemic patients
Mutation analysis of both clone 1 and Leu1 have been carried out in five patients with heterozygous deletion of 13q14.3. The postulated coding region of Leu1 was amplified by RT-PCR using primers C12T7(5)-F and C12T3(6)-R. 15 Only the shorter transcript has been cloned and sequenced and no mutations were found. This concurs with data from other groups. 15, 16 A polymorphic change (T to A substitution), 10 nucleotides from the ATG codon of exon 1 of Leu1 was detected resulting in a cysteine to serine amino acid substitution in the predicted protein sequence of the Leu1 gene. Using primers C12T7 (5)-F 15 and Leu1 ex 1 internal (Table 1) , the T to A substitution was confirmed on DNA from 20 normal individuals, with a frequency compatible with a novel polymorphism.
The remaining eight exons of clone 1, plus their intronexon boundaries (Table 2) were amplified using a combination of primers (Table 1) , both at the genomic and cDNA level. All PCR products were cloned and sequenced but no mutations were demonstrated.
Cellular localization of Leu1 and clone 1 transcripts
cDNA was generated from nuclear and cytoplasmic fractions of RNA isolated from both CLL patients (n = 4) and normal controls (n = 2). When RT-PCR was performed using primers for amplification of exons 3 to 5 and exons 5 to 7, respectively, a signal was detected in the nuclear but not the cytoplasmic fraction. By contrast, amplification of Leu1 gave rise to a signal detectable in the cytoplasmic fraction of the RNA preparation ( Figure 6 ). Amplification of the intergenic, unspliced transcript of RAD 50 32 was used as a control for this experiment. The unspliced RAD 50 transcript is retained in the nucleus of all cells. These data show that the short form of Leu1 is localized in the cytoplasm, a feature of mature and processed mRNA, whereas the longer versions of the gene are almost exclusively localized in the nucleus, suggesting that they may represent a more immature or non-translated RNA.
Discussion
Our study has further redefined the RMD on 13q14.3 in CLL patients, it identified and characterized two CpG islands from within the RMD, ordered and characterized several novel DNA and cDNA probes and identified a novel alternative spliced Leu1 transcript.
Deletion of 13q14.3 was demonstrated in 33 (51.5%) of the 64 patients analyzed, of whom nine (14%) had homozygous deletion and 24 (37.5%) carried heterozygous deletion. The region of deletion (265 kb) overlaps with that described by some investigators, 3, 12, 14 but not others. 1 The combined data 3, 12, 14 and our study define a 230 kb RMD, between markers D13S319 and D13S25, making this the most common area of deletion in CLL patients. Consequently, this region remains the main focus of investigation in CLL.
We were able to identify two alternatively spliced transcripts positioned within the region of deletion. One transcript corresponded to the previously identified Leu1 mRNA, although our cDNA differed from the previously published sequence by 1 bp, encoding for a peptide longer (an extra 6 AA) than published. 15 With the exception of a novel polymorphic T to A substitution in exon 1, no inactivation mutations of this clone were demonstrated in five patients with heterozygous deletion of 13q14.3.
The second transcript represents an alternatively spliced form of Leu1, containing exon 1 of Leu1 plus an additional eight novel exons. These exons were identified using cDNA library screening (exons 1b, 3, 4, [7] [8] [9] and RACE PCR (exons 5 and 6) . The longest open reading frame of clone 1 is 297 bp,
Figure 6
RT-PCR analysis of RAD50 and alternative spliced forms of clone 1. RT-PCR was carried out according to the protocol described in the text. The individual primers used in the different reactions are listed below each set of reactions. The spliced and unspliced forms of RAD50 are marked with an arrow.
Leukemia potentially encoding for a 99 AA peptide. As with Leu1, no mutations were found within the sequence of clone 1 in any of the five heterozygous CLL patients analysed.
RT-PCR amplification of Leu1 and clone 1 was demonstrated in both normal and malignant lymphocytes. However, only the expression of Leu1 (exons 1 and 2) was detectable by Northern blot analysis.
Clone 1 has been demonstrated to exist as a longer, alternative transcript of Leu1, suggesting that the functions of the two clones may be related. Some of the most compelling evidence for Leu1 being involved in CLL, is provided by data from Liu et al 15 showing the minimal region of deletion in their patients to be 10 kb, centromeric of D13S319 with Leu1 being contained within this 10 kb. However, as in our study, the authors found no mutation on the retained allele of Leu1 in patients with heterozygous 13q14.3 deletions.
Other groups have defined a more telomeric region of deletion. 13, 14 Exons of clone 1 also fall within these regions, again suggesting that these deletions may inactivate clone 1.
Knudson's 33 two-hit theory of tumour suppressor gene inactivation would predict that all patients with deletion of a tumour suppressor gene from one allele would have a mutation of that gene on the retained allele. This model may not apply in CLL. Recently published data found no mutations in the entire region in three patients with heterozygous deletion of 13q14. 3, 16 suggesting that modes of gene inactivation other than mutation may be relevant in this group of patients. It is possible that expression of the retained allele is affected by methylation patterns or haploinsufficiency. Aberrant methylation of a CpG island has been shown to correlate with transcriptional silencing of the suppressor of cytokine signalling gene, SOCS-1, in hepatocellular carcinoma. 34 Haploinsufficiency has recently been shown to be a mechanism associated with the loss of AML1 gene leading to familial thrombocytopenia with a propensity to develop acute myeloid leukemia. 35, 36 These possibilities have yet to be fully explored in the context of 13q14.3 deletion in CLL. We have demonstrated that a CpG island upstream of Leu1 and proximal to D13S319 is completely unmethylated in all samples investigated including patients with heterozygous deletion of 13q14.3, ruling out aberrant methylation of this CpG island as a candidate mechanism of gene inactivation. A second CpG island downstream of Leu1 was fully methylated in all control and leukemic samples.
The functions of Leu1 and cDNA clone 1 are unknown. The lack of an extensive open reading frame in any of the splice versions of clone 1 and the nuclear localization of its mRNA suggest that this transcript may not encode for a peptide. However, other similarly large transcripts, initially thought to be sterile, have subsequently been shown to encode for a small functioning peptide. 37 It is also feasible that, rather than encoding for a peptide, the RNA of clone 1 may function as a noncoding RNA molecule. Many such molecules have now been described and their functions appear to be as diverse as those of peptides H19, a molecule in this group, that has been shown to have tumor suppressor properties. 38 The mRNA of clone 1 may act to modulate Leu1 localization and expression. Consequently, loss of any part of clone 1 may have an effect on expression of Leu1. Until the function of Leu1 and the associated cDNA clone 1 can be elucidated, both transcripts remain candidate tumor suppressor gene cDNAs from the deleted region at 13q14.3 in B cell CLL.
Despite extensive studies by many groups, no tumor suppressor gene involved in the pathogenesis of B cell CLL has been defined at 13q14.3. It is conceivable that the gene rel-evant in the pathogenesis of B cell CLL acts via a mechanism previously undescribed for tumor suppressor genes and discussed above. Alternatively, the deletions identified in our study and by others may have an effect on control elements of a gene located outside the RMD. This model has recently been described in a familial case of alpha thalassemia. 39 Deletion of 13q14.3 could have a similar effect on a yet unknown gene or on any of the genes already described from the region.
Prior to submission of this manuscript a report was published by Mabuchi et al, 40 describing the identification of three genes (CLLD6, 7 and 8). These genes are outside our RMD and centromeric to the area of minimal deletion described previously by the authors themselves 14 and those described by others. 1, 2, 12, 15, 16 Consequently, their implication in CLL remains to be demonstrated.
Simultaneously with the completion of our manuscript, a paper was published reporting on the identification of a Leu1 alternative splice form (referred to as the BCMS gene), encompassing 47 exons with the first common exon being Leu1 exon 1. 41 Inspite of minor variations in the reported sequence of Wolf et al ( . Like Wolf and colleagues, we also identified several other sequences in this region (data not shown). However, all sequences identified in our study were screened for the presence of splice donor and acceptor sites and ORFs in the 5Ј to 3Ј orientation of Leu1. Only the exons included in this report fully comply with these criteria. Many of the 'exons' suggested by Wolf et al did not fulfil such criteria and we believe this accounts for the major differences between the two studies. Wolf states that '. . . only 14 of the 50 exons of BCMS possess continuous ORF, and it is notable that no transcript was identified which consists only of a combination of these exons.' 41 Wolf and colleagues also carried out mutation analysis, but only applied to exons 17, 28, 29, 33 , and 40 of BCMS gene which corresponds to exons 3-7 of our clone 1 (see above) suggesting that despite the large number of additional exons, they also believed that these were genuine exons worthy of investigation.
Finally, a report by Bullrich and colleagues 42 recently published, describes an alternative splice variant of Leu2 gene, which they called ALT1. Since ALT1 falls outside our RMD and no mutations were found in CLL patients with heterozygous deletion of 13q14.3 it cannot be considered as a candidate gene. The search for the 'CLL gene' should therefore continue.
